- Home
- SGD vs CYCC Comparison
SGD vs CYCC Comparison
Compare SGD & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGD
- CYCC
- Stock Information
- Founded
- SGD 2021
- CYCC 1992
- Country
- SGD United States
- CYCC Malaysia
- Employees
- SGD N/A
- CYCC N/A
- Industry
- SGD
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- SGD
- CYCC Health Care
- Exchange
- SGD Nasdaq
- CYCC Nasdaq
- Market Cap
- SGD 1.8M
- CYCC 8.3M
- IPO Year
- SGD N/A
- CYCC N/A
- Fundamental
- Price
- SGD $0.78
- CYCC $0.24
- Analyst Decision
- SGD
- CYCC
- Analyst Count
- SGD 0
- CYCC 0
- Target Price
- SGD N/A
- CYCC N/A
- AVG Volume (30 Days)
- SGD 94.0K
- CYCC 4.2M
- Earning Date
- SGD 08-22-2025
- CYCC 08-13-2025
- Dividend Yield
- SGD N/A
- CYCC N/A
- EPS Growth
- SGD N/A
- CYCC N/A
- EPS
- SGD N/A
- CYCC N/A
- Revenue
- SGD $175,906.00
- CYCC $14,000.00
- Revenue This Year
- SGD N/A
- CYCC $137.21
- Revenue Next Year
- SGD N/A
- CYCC N/A
- P/E Ratio
- SGD N/A
- CYCC N/A
- Revenue Growth
- SGD 253.11
- CYCC N/A
- 52 Week Low
- SGD $0.65
- CYCC $0.22
- 52 Week High
- SGD $9.98
- CYCC $39.84
- Technical
- Relative Strength Index (RSI)
- SGD 38.79
- CYCC 24.28
- Support Level
- SGD $0.78
- CYCC $0.31
- Resistance Level
- SGD $0.90
- CYCC $0.34
- Average True Range (ATR)
- SGD 0.08
- CYCC 0.05
- MACD
- SGD -0.02
- CYCC 0.10
- Stochastic Oscillator
- SGD 1.00
- CYCC 8.57
About SGD Safe and Green Development Corporation
Safe & Green Development Corp is a real estate development company that focuses on the development of sites using purpose built, prefabricated modules built from both wood & steel, sourced from one of Safe and Green Holdings factories. The company's business model is flexible and it anticipates developing properties on its own and also through joint ventures in which it partners with third-party equity investors or other developers.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.